Company Filing History:
Years Active: 2006-2015
Title: Innovations and Contributions of Inventor Werner E. Haas
Introduction
Werner E. Haas is a notable inventor based in Oeiras, Portugal, who has made significant strides in the pharmaceutical field. With a total of three patents to his name, his work focuses on the treatment and prevention of diseases through novel compounds. His expertise in releasing carbon monoxide for therapeutic applications stands out in the realm of modern medicine.
Latest Patents
Haas' latest patents demonstrate his cutting-edge approach to treating chronic inflammatory diseases. His innovative method involves the administration of compounds capable of releasing carbon monoxide in vivo. This method shows potential for addressing a variety of inflammatory conditions, such as rheumatoid arthritis and diseases with significant inflammatory components, including atherosclerosis, stroke, coronary disease, and Alzheimer's disease. Furthermore, these carbon monoxide-releasing compounds can be effectively combined with established drug vectors and anti-inflammatory medications, such as aspirin, enhancing their therapeutic efficacy.
Career Highlights
Throughout his career, Werner E. Haas has worked with organizations focused on pharmaceutical research and development. Notably, he was associated with Alfama - Investigação e Desenvolvimento de Produtos Farmacêuticos, Lda., where his contributions to innovative medical treatments and drug formulation were invaluable.
Collaborations
Collaborating with talented professionals has been a hallmark of Haas' career. Some of his noteworthy coworkers include Carlos C. Romão and Ana Cristina Fernandes, both of whom have contributed to the advancement of knowledge in pharmaceutical innovations.
Conclusion
Werner E. Haas exemplifies the spirit of innovation and dedication in the field of medicine. His patents underscore the potential of carbon monoxide-releasing compounds in treating various severe health conditions. As he continues to collaborate with others in the pharmaceutical sector, his work is likely to lead to groundbreaking advancements in disease treatment and prevention.